Sante Capital Fund, LP Fate Therapeutics Inc Transaction History
Sante Capital Fund, LP
- $48.9 Million
- Q3 2022
Shares
2 transactions
Others Institutions Holding FATE
# of Institutions
185Shares Held
123MCall Options Held
15KPut Options Held
14K-
Redmile Group, LLC San Francisco, CA13.2MShares$36.3 Million2.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$29.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$27.9 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA8.22MShares$22.7 Million1.5% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$15.4 Million0.6% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $268M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...